The guideline on Antisocial Personality Disorder, commissioned by NICE and developed by the National Collaborating Centre for Mental Health, sets out clear, evidence- and consensus-based recommendations for staff working in health and social care and the criminal justice system on how to treat, manage and prevent antisocial personality disorder.

The NICE guideline takes the first comprehensive view of antisocial personality disorder and is an invaluable resource to enable professionals to improve the outcomes for people with the disorder, who often have significant impairments. Being able to prevent and properly manage antisocial personality disorder will also have considerable social implications.

This publication brings together all of the evidence that led to the recommendations in the NICE guideline, and draws on a wide literature, including evidence for the management of offending behaviour. It includes a review of interventions in children and young people with conduct disorder, which may prevent the development of antisocial personality disorder; risk assessment and management; organisation and experience of care; and a range of interventions for adults with antisocial personality disorder, including psychological interventions, treatment for comorbid disorders, therapeutic communities and pharmacological interventions. The book also contains a useful overview of antisocial personality disorder, including ethical considerations.

Contents

• GUIDELINE DEVELOPMENT GROUP MEMBERS
• 1. PREFACE
  • 1.1. NATIONAL GUIDELINES
  • 1.2. THE NATIONAL ANTISOCIAL PERSONALITY DISORDER GUIDELINE
• 2. ANTISOCIAL PERSONALITY DISORDER
  • 2.1. INTRODUCTION
  • 2.2. THE DISORDER
  • 2.3. AETIOLOGY
  • 2.4. PRESENTATION IN HEALTHCARE AND OTHER SETTINGS
  • 2.5. USE OF HEALTH SERVICE RESOURCES AND OTHER COSTS
  • 2.6. TREATMENT AND MANAGEMENT IN THE NHS
  • 2.7. THE DANGEROUS AND SEVERE PERSONALITY DISORDER INITIATIVE
  • 2.8. THE ORGANISATION AND COORDINATION OF TREATMENT AND CARE
  • 2.9. ASSESSMENT
  • 2.10. ETHICAL CONSIDERATIONS IN ANTISOCIAL PERSONALITY DISORDER
• 3. METHODS USED TO DEVELOP THIS GUIDELINE
  • 3.1. OVERVIEW
  • 3.2. THE SCOPE
  • 3.3. THE GUIDELINE DEVELOPMENT GROUP
  • 3.4. CLINICAL QUESTIONS
  • 3.5. SYSTEMATIC CLINICAL LITERATURE REVIEW
  • 3.6. HEALTH ECONOMICS METHODS
  • 3.7. STAKEHOLDER CONTRIBUTIONS
  • 3.8. VALIDATION OF THE GUIDELINE
• 4. ORGANISATION AND EXPERIENCE OF CARE
  • 4.1. INTRODUCTION
  • 4.2. ORGANISATION AND DELIVERY OF CARE
  • 4.3. TRAINING, SUPERVISION AND SUPPORT
  • 4.4. SERVICE USER EXPERIENCE OF CARE AND SERVICES
  • 4.5. CARER EXPERIENCE
  • 4.6. OVERALL SUMMARY
• 5. INTERVENTIONS IN CHILDREN AND ADOLESCENTS FOR THE PREVENTION OF ANTISOCIAL PERSONALITY DISORDER
  • 5.1. INTRODUCTION
  • 5.2. RISK FACTORS
  • 5.3. EARLY INTERVENTIONS
  • 5.4. INTERVENTIONS FOR CHILDREN WITH CONDUCT PROBLEMS
  • 5.5. COORDINATION OF CARE
• 6. RISK ASSESSMENT AND MANAGEMENT
  • 6.1. INTRODUCTION
  • 6.2. ASSESSMENT OF VIOLENCE RISK
  • 6.3. RISK MANAGEMENT
• 7. INTERVENTIONS FOR PEOPLE WITH ANTISOCIAL PERSONALITY DISORDER AND ASSOCIATED SYMPTOMS AND BEHAVIOURS
  • 7.1. INTRODUCTION
  • 7.2. PSYCHOLOGICAL INTERVENTIONS FOR ANTISOCIAL PERSONALITY DISORDER
  • 7.3. TREATMENT OF COMORBID DISORDERS IN PEOPLE WITH ANTISOCIAL PERSONALITY DISORDER
  • 7.4. THERAPEUTIC COMMUNITY INTERVENTIONS FOR PEOPLE WITH ANTISOCIAL PERSONALITY DISORDER AND ASSOCIATED SYMPTOMS AND BEHAVIOURS
  • 7.5. PHARMACOLOGICAL INTERVENTIONS FOR ANTISOCIAL PERSONALITY DISORDER
  • 7.6. RESEARCH RECOMMENDATIONS
• 8. SUMMARY OF RECOMMENDATIONS
  • GUIDANCE
  • RESEARCH RECOMMENDATIONS
• 9. APPENDICES
  • APPENDIX 1. SCOPE FOR THE DEVELOPMENT OF THE CLINICAL GUIDELINE
  • APPENDIX 2. DECLARATIONS OF INTERESTS BY GDG MEMBERS
  • APPENDIX 3. SPECIAL ADVISERS TO THE GUIDELINE DEVELOPMENT GROUP
  • APPENDIX 4. STAKEHOLDERS WHO RESPONDED TO EARLY REQUESTS FOR EVIDENCE
  • APPENDIX 5. STAKEHOLDERS AND EXPERTS WHO SUBMITTED COMMENTS IN RESPONSE TO THE CONSULTATION DRAFT OF THE GUIDELINE
  • APPENDIX 6. RESEARCHERS CONTACTED TO REQUEST INFORMATION ABOUT UNPUBLISHED OR SOON-TO-BE PUBLISHED STUDIES
  • APPENDIX 7. ANALYTIC FRAMEWORK AND CLINICAL QUESTIONS
  • APPENDIX 8. SEARCH STRATEGIES FOR THE IDENTIFICATION OF CLINICAL STUDIES
  • APPENDIX 9. CLINICAL STUDY DATA EXTRACTION FORM
  • APPENDIX 10. QUALITY CHECKLISTS FOR CLINICAL STUDIES AND REVIEWS
  • APPENDIX 11. SEARCH STRATEGIES FOR THE IDENTIFICATION OF HEALTH ECONOMICS EVIDENCE
  • APPENDIX 12. QUALITY CHECKLIST FOR ECONOMIC STUDIES
  • APPENDIX 13. DATA EXTRACTION FORM FOR ECONOMIC STUDIES
  • APPENDIX 14. EVIDENCE TABLES FOR ECONOMIC STUDIES
  • APPENDIX 15. CHARACTERISTICS OF REVIEWED STUDIES
  • APPENDIX 16. CLINICAL EVIDENCE FOREST PLOTS
  • APPENDIX 17. STUDY CHARACTERISITCS OF RISK FACTORS FOR DEVELOPING ANTISOCIAL PERSONALITY DISORDER
• 10. REFERENCES
• 11. ABBREVIATIONS

The views presented in this book do not necessarily reflect those of the British Psychological Society, and the publishers are not responsible for any error of omission or fact. The British Psychological Society is a registered charity (no. 229642).